Let’s Talk Medtech Guardant Health's Meteoric Rise in Cancer Detection
Sep 8, 2022
Helmy Eltoukhy, Co-founder and CEO of Guardant Health, dives into the groundbreaking evolution of liquid biopsy, transforming cancer detection. He shares insights about the company's growth and the launch of a new colorectal cancer screening test designed for average-risk individuals. Eltoukhy discusses the pivotal shift from invasive procedures to innovative blood tests and how going public has fueled advancements in their technology. He emphasizes the urgency of early detection and the evolving landscape of medical reimbursement in the diagnostics field.
AI Snips
Chapters
Transcript
Episode notes
Guardant Health's 10-Year Journey
- Guardant Health celebrated its 10-year anniversary, reflecting on its ambitious goal of revolutionizing cancer care.
- They aimed to provide information about any point in the cancer care continuum with a simple blood test.
Going Public: A Milestone for Guardant Health
- Guardant Health transitioned from a private to a public company in 2018, gaining access to capital markets and increased credibility.
- This transition has accelerated their work and provided the resources to tackle the challenge of cancer.
Guardant360 CDX: A Pioneering Liquid Biopsy
- Guardant360 CDX, launched in 2014, was the first clinically-based liquid biopsy based on sequencing.
- In 2020, it became the first FDA-approved liquid biopsy of its kind, revolutionizing cancer diagnostics by replacing invasive biopsies with a simple blood draw.